Advice

following a full submission:

imiquimod (Zyclara®) is accepted for restricted use within NHSScotland.

Indication under review: for the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.

SMC restriction: for the treatment of large field actinic keratosis (>25cm2).

In two randomised, double-blind, phase III studies, a greater proportion of adults with actinic keratosis affecting an area >25cm2 on the face or balding scalp achieved complete clearance when treated with imiquimod 3.75% cream compared with vehicle.

Medicine details

Medicine name:
imiquimod (Zyclara)
SMC ID:
SMC2211
Indication:

Topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis (AK) of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.

Pharmaceutical company
Meda Pharmaceuticals Ltd
BNF chapter
Skin
Submission type
Full
Status
Restricted
Date advice published:
11 November 2019